New approaches to stroke prevention in atrial fibrillation

Current Treatment Options in Cardiovascular Medicine

Volumn 12, Issue 3, 2010, Pages 261-273

  Testai, Fernando D ^a   Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BETA THROMBOGLOBULIN; BETRIXABAN; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C9; D DIMER; DABIGATRAN; IBUPROFEN; IRBESARTAN; MENADIONE EPOXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIVAROXABAN; SALICYLHYDROXAMIC ACID; VASCULOTROPIN; WARFARIN; XIMELAGATRAN;

AGING; ALCOHOLISM; ANTICOAGULATION; ASTHMA; BACTERIAL ENDOCARDITIS; BLEEDING; BLOOD COMPONENT; BLOOD FLOW; BLOOD VESSEL WALL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 4Q; CLINICAL EVALUATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; ECHOCARDIOGRAPHY; EMBOLISM; FIBRINOLYSIS; FRAMESHIFT MUTATION; GANGRENE; GASTROINTESTINAL HEMORRHAGE; GENE LOCUS; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MALIGNANT HYPERTENSION; MEDICAL SOCIETY; NOSE POLYP; OBESITY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDITIS; PRACTICE GUIDELINE; PREGNANCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY ALKALOSIS; REVIEW; REYE SYNDROME; RHINITIS; RISK REDUCTION; SINUS RHYTHM; SKIN NECROSIS; STROKE; THROMBOCYTE; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOE GANGRENE; TRANSIENT ISCHEMIC ATTACK; TREATMENT CONTRAINDICATION; VIRUS INFECTION;

EID: 77953538663     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-010-0071-z     Document Type: Review

References (50)

1. Lip GYH, Tse H-F: Management of atrial fibrillation.Lancet 2007, 370:604-618.
2. Callans DJ, Laine C, Goldmann D: In the clinic: Atrial fibrillation. Ann Intern Med 2008, 149:ITC5-1-ITC5-16.
3. Aguilar MI, Hart R: Oral anticoagulants versusantiplatelet therapy for preventing stroke inpatients with nonvalvular atrial fibrillation and nohistory of stroke or transient ischemic attacks.Stroke 2008, 39:1399-1400.
4. Gorelick PB, Weber MA: Handbook of Stroke Preventionand Treatment. London: Current MedicineGroup; 2007:17.
5. Watson T, Shantsila E, Lip GYH: Mechanisms ofthrombogenesis in atrial fibrillation: Virchow'striad revisited. Lancet 2009, 373:155-166.
6. Brieger DB, Freedman SB: Delirium cordis: can wepredict the onset of atrial fibrillation? Lancet 2009, 373:698-700.
7. Schnabel RE, Sullivan LM, Levy D, et al.: Developmentof a risk score for atrial fibrillation (FraminghamHeart Study): A community-based cohortstudy. Lancet 2009, 373:739-745.
8. Wallmann D, Tuller D, Wustman K, et al.: Frequentatrial premature beats predict paroxysmal atrialfibrillation in stroke patients. An opportunity for anew diagnostic strategy. Stroke 2007, 38:2292-2294.
9. Liao J, Khalid Z, Scallan C, et al.: Noninvasivecardiac monitoring for detecting paroxysmal atrialfibrillation or flutter after acute ischemic stroke. Asystematic review. Stroke 2007, 38:2935-2940.
10. Tayal AH, Tian M, Kelly KM, et al.: Atrial fibrillationdetected by mobile cardiac outpatient telemetry incryptogenic TIA or stroke. Neurology 2008, 71:1696-1701.
11. Gretarsdottir S, Thorleifsson G, Manolescu A, et al.:Risk variants for atrial fibrillation on 4q25 associatewith ischemic stroke. Ann Neurol 2008, 64:402-409.
12. Gudbjartsson DF, Holm H, Gretarsdottir S, et al.: Asequence variant in ZFHX3 on 16q22 associateswith atrial fibrillation and ischemic stroke. NatGenet 2009, 41:876-878.
13. Hodgson-Zingman DM, Karst ML, Zingman LV, et al.: Atrial natriuretic peptide frameshift mutationin familial atrial fibrillation. N Engl J Med 2008, 359:158-165.
14. Stroke Prevention in Atrial Fibrillation Study: Finalresults. Circulation 1991, 84:527-539.
15. Warfarin versus aspirin for prevention of thromboembolismin atrial fibrillation: Stroke Prevention inAtrial Fibrillation II Study. Lancet 1994, 343:687-691.
16. Adjusted-dose warfarin versus low-intensity, fixeddosewarfarin plus aspirin for high-risk patientswith atrial fibrillation: Stroke Prevention in AtrialFibrillation III randomised clinical trial. Lancet1996, 348:633-638.
17. Petersen P, Boysen G, Godtfredsen J, et al.: Placebocontrolled, randomised trial of warfarin andaspirin for prevention of thromboembolic complicationsin chronic atrial fibrillation. The CopenhagenAFASAK study. Lancet 1989, 1:175-179.
18. Gulløv AL, Koefoed BG, Petersen P, et al.: Fixedminidose warfarin and aspirin alone and in combinationvs adjusted-dose warfarin for stroke preventionin atrial fibrillation: Second CopenhagenAtrial Fibrillation, Aspirin, and AnticoagulationStudy. Arch Intern Med 1998, 158:1513-1521.
19. Hellemons BS, Langenberg M, Lodder J, et al.:Primary prevention of arterial thromboembolismin non-rheumatic atrial fibrillation in primary care:randomised controlled trial comparing twointensities of coumarin with aspirin. BMJ 1999, 319:958-964.
20. Secondary prevention in non-rheumatic atrial fibrillationafter transient ischaemic attack or minorstroke. EAFT (European Atrial Fibrillation Trial)Study Group. Lancet 1993, 342:1255-1262.
21. van Walraven C, Hart RG, Singer DE, et al.: Oralanticoagulants vs aspirin in nonvalvular atrialfibrillation: An individual patient meta-analysis.JAMA 2002, 288:2441-2448.
22. Goldstein LB, Adams R, Alberts MJ, et al.; AmericanHeart Association; American Stroke AssociationStroke Council: Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsoredby the Atherosclerotic Peripheral VascularDisease Interdisciplinary Working Group; CardiovascularNursing Council; Clinical Cardiology Council;Nutrition, Physical Activity, and Metabolism Council;and the Quality of Care and Outcomes ResearchInterdisciplinary Working Group. Circulation 2006, 113:e873-e923 (Published erratum appears inCirculation 2006, 114:e617).
23. Stroke Risk in Atrial Fibrillation Working Group:Independent predictors of stroke in patients withatrial fibrillation. A systematic review. Neurology2007, 69:546-554.
24. Stroke Risk in Atrial Fibrillation Working Group:Comparison of 12 risk stratification schemes topredict stroke in patients with nonvalvular atrialfibrillation. Stroke 2008, 39:1901-1910.
25. Singer DE, Chang Y, Fang MC, et al.: The net clinicalbenefit of warfarin anticoagulation in atrial fibrillation.Ann Intern Med 2009, 151:297-305.
26. Hart RG, Halperin JL: Do current guidelines resultin overuse of warfarin anticoagulation in patientswith atrial fibrillation? Ann Intern Med 2009, 151:355-356.
27. Goodman LS, Gilman A: Pharmacological Basis ofTherapeutics, edn 5th. New York: MacmillanPublishing Co.; 1975:1355-1361.
28. Gorelick PB: Combining aspirin with oral anticoagulanttherapy. Is this a safe and effective practicein patients with atrial fibrillation? Stroke 2007, 38:1652-1654.
29. Budnitz DS, Shehab N, Kegler SR, Richards CL:Medication use leading to emergency departmentvisits for adverse drug events in older adults. AnnIntern Med 2007, 147:755-765.
30. The International Warfarin PharmacogeneticConsortium: Estimation of the warfarin dose withclinical and pharmacogenetic data. N Engl J Med2009, 360:753-764.
31. Ioannidis JPA: Personalized genetic prediction: toolimited, too expensive, or too soon? Ann Intern Med2009, 150:139-141.
32. Eckman MH, Rosand J, Greenberg ST, Gage BF:Cost-effectiveness of using pharmacogenetic informationin warfarin dosing for patients with nonvalvularatrial fibrillation. Ann Intern Med 2009, 150:73-83.
33. Eckman MH, Wong LKS, Soo YOY, et al.: Patientspecificdecision-making for warfarin therapy innonvalvular atrial fibrillation. How will screeningwith genetics and imaging help? Stroke 2008, 39:3308-3315.
34. Rosove MH, Grody WW: Should we be applyingwarfarin pharmacogenetics to clinical practice?No, not now. Ann Intern Med 2009, 151:270-273.
35. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke inpatients who have nonvalvular atrial fibrillation.Ann Intern Med 2007, 146:857-867.
36. Catella-Lawson F, Reilly MP, Kapoor SC, et al.:Cyclooxygenase inhibitors and the antiplateleteffects of aspirin. N Engl J Med 2001, 345:1809-1817.
37. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al.: Clopidogrel plusaspirin versus oral anticoagulation for atrial fibrillationin the Atrial fibrillation Clopidogrel Trialwith Irbesartan for prevention of Vascular Events(ACTIVE W): A randomised controlled trial. Lancet2006, 367:1903-1912.
38. ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, et al.: Effect of clopidogrel added to aspirin inpatients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.In this study, the combination of aspirin and clopidogrelwas superior to aspirin monotherapy in preventing stroke;however, patients receiving dual antiplatelet treatment had ahigher rate of hemorrhagic complications.
39. Mega JL, Close SL, Wiviott SD, et al.: Cytochromep-450 polymorphisms and response to clopidogrel.N Engl J Med 2009, 360:354-362.
40. Gilard M, Arnaud B, Cornily JC, et al.: Influence ofomeprazole on the antiplatelet action of clopidogrelassociated with aspirin: the randomized, doubleblindOCLA (Omeprazole CLopidogrel Aspirin)study. J Am Coll Cardiol 2008, 51:256-260.
41. Holmes DR, Reddy VY, Turi ZG, PROTECT AFInvestigators, et al.: Percutaneous closure of the leftatrial appendage versus warfarin therapy for preventionof stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009, 374:534-542.This study concluded that the atrial occluder may be analternative treatment for individuals who are not candidatesfor oral anticoagulation therapy. However, a higher rate ofcomplications was seen in the surgical arm.
42. Ad N, Henry L, Hunt S, et al.: The Cox-Maze IIIprocedure success rate: comparison by electrocardiogram, 24-hour holter monitoring and long-termmonitoring. Ann Thorac Surg 2009, 88:101-105.Surgical ablation of AF is an appealing approach, as it maycure this type of arrhythmia and decrease the risk of stroke.
43. Bungard TJ, Ghali WA, Teo KK, et al.: Why dopatients with atrial fibrillation not receive warfarin?Arch Intern Med 2000, 160:41-46.
44. Olsson SB, Executive Steering Committee of theSPORTIF III Investigators: Stroke prevention withthe oral direct thrombin inhibitor ximelagatrancompared with warfarin in patients with non-valvularatrial fibrillation (SPORTIF III): randomised controlledtrial. Lancet 2003, 362:1691-1698.
45. Albers GW, Diener HC, Frison L, SPORTIF ExecutiveSteering Committee for the SPORTIF V Investigators, et al.: Ximelagatran vs warfarin for stroke preventionin patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 2005, 293:690-698.
46. Connolly SJ, Ezekowitz MD, Yusuf S, et al.: RE-LYSteering Committee and Investigators: Dabigatranversus warfarin in patients with atrial fibrillation.N Engl J Med 2009, 361:1139-1151.Dabigatran was not inferior to warfarin in preventingstroke in AF patients. Its efficacy, pharmacokinetics, andinteraction/safety profile make dabigatran an appealingalternative to warfarin for the treatment of AF patients atrisk for stroke.
47. Sherman DG: Stroke prevention in atrial fibrillation.Pharmacologic rate versus rhythm control.Stroke 2007, 38:615-617.
48. Zimetbaum PJ: Dronedarone for atrial fibrillation-an odyssey. JAMA 2009, 360:1811-1813.
49. Hohnloser SH, Crijns HJGM, van Eickels M: et al; forthe ATHENA Investigators: Effect of dronedaroneon cardiovascular events in atrial fibrillation. NEngl J Med 2009, 360:668-678.
50. Gillis AM: Angiotensin-receptor blockers for preventionof atrial fibrillation-a matter of timing ortarget? N Engl J Med 2009, 360:1669-1672.